

Design, synthesis, and biological evaluation of quino- line-8-sulfonamides as inhibitors of the tumor cell spe- cific M2 isoform of pyruvate kinase

Krzysztof Marciniak ^{1,*}, Artur Beberok ², Zuzanna Rzepka ², Elwira Chrobak ¹, Małgorzata Latocha ³,
Dorota Wrześniok ², and Stanisław Boryczka¹

¹ Department of Organic Chemistry, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland

² Department of Pharmaceutical Chemistry, Jagiellońska 4, 41-200 Sosnowiec, Poland

³ Department of Molecular Biology, Jagiellońska 4, 41-200 Sosnowiec, Poland

Correspondence: kmarciniak@um.edu.pl

Table S1. Interaction of compounds **9a–e** with target proteins

Protein		Ligand		Interaction	
Name	Residue	Name	Residue	Type	Distance [Å]
G1N	A:Tyr390	9a	Sulfonamide oxygen	Conventional hydrogen bond	1.76
	B:Lys311		Triazole nitrogen	Conventional hydrogen bond	2.67
	A:Leu353		Sulfonamide nitrogen	Conventional hydrogen bond	2.42
	A:Ile389		Sulfonamide oxygen	Carbon hydrogen bond	2.75
	A:Asp354		Pyridine ring C2	Carbon hydrogen bond	2.29
	B:Asp354		Pyridine ring C2'	Carbon hydrogen bond	2.82
	A:Met30		Triazole ring	π -Sulfur	4.07
	A:Phe26		Benzene ring	π -Sulfur	5.89
	A:Phe26		Benzene ring	π - π - Stacked	5.36
	A:Phe26		Pyridine ring	π - π T-shaped	5.94
	A:Phe26		Benzene ring	π - π T-shaped	4.53
	A:Phe26		Benzene ring	π - π T-shaped	5.18
	A:Phe26		Pyridine ring	π - π T-shaped	5.13
	A:Leu27		Chlorine atom	Alkyl	4.42
	B:Leu394		Chlorine atom	Alkyl	5.43
	A:Leu394		Benzene ring	π -Alkyl	4.44
	A:Leu394		Pyridine ring	π -Alkyl	4.87
	B:Leu27		Pyridine ring	π -Alkyl	5.36
	B:Met30		Pyridine ring	π -Alkyl	5.49
	A:Leu353		Triazole ring	π -Alkyl	4.41
	A:Met30		Benzene ring	π -Alkyl	5.13
	A:Met30		Pyridine ring	π -Alkyl	4.12
	A:Tyr390	9b	Sulfonamide oxygen	Conventional hydrogen bond	1.97
	A:Leu353		Sulfonamide oxygen	Carbon hydrogen bond	2.58
	A:Ile389		Sulfonamide oxygen	Carbon hydrogen bond	2.35
	A:Leu353		Pyridine ring C2	Carbon hydrogen bond	2.70
	A:Asp354		Pyridine ring C2	Carbon hydrogen bond	2.27
	B:Leu353		Ethyl group	Carbon hydrogen bond	2.73
	A:Phe26		Sulfonamide sulfur	π -Sulfur	5.16
	B:Phe26		Benzene ring	π - π T-shaped	5.45
	B:Phe26		Pyridine ring	π - π T-shaped	5.14
	B:Leu394		Ethyl group	Alkyl	4.66
	B:Leu394		Ethyl group	Alkyl	4.87
	A:Leu394		Benzene ring	π -Alkyl	4.48
	A:Leu394		Pyridine ring	π -Alkyl	5.20
	A:Met30		Triazole ring	π -Alkyl	4.59
	A:Leu353		Triazole ring	π -Alkyl	5.44
	B:Lys311		Triazole ring	π -Alkyl	4.86
	B:Lys311	9c	Sulfonamide oxygen	Conventional hydrogen bond	1.95
	B:Leu394		Ester carbonyl oxygen	Carbon hydrogen bond	2.42
	A:Leu353		Benzene ring	π -Sigma	2.47
	A:Met30		Triazole ring	π -Sulfur	4.82
	A:Phe26		Triazole ring	π - π -Stacked	3.16
	A:Phe26		Benzene ring	π - π T-shaped	4.80
	B:Phe26		Triazole ring	π - π T-shaped	5.38
	A:Leu27		Ethyl group	Alkyl	4.64

	B:Leu394	Ethyl group	Alkyl	5.44
	A:Leu353	Pyridine ring	π -Alkyl	3.97
	B:Lys311	Sulfonamide oxygen	Conventional Hydrogen Bond	1.83
	A:Met30	Triazole ring	π -Sulfur	4.95
	A:Phe26	Triazole ring	π - π -Stacked	3.33
	A:Phe26	Benzene ring	π - π T-shaped	5.01
	A:Phe26	Pyridine ring	π - π T-shaped	5.21
	B:Phe26	Triazole ring	π - π T-shaped	5.37
	B:Ile389	Butyl group	Alkyl	4.77
	B:Leu394	Butyl group	Alkyl	4.07
	A:Leu353	Benzene ring	π -Alkyl	3.79
	A:Leu353	Pyridine ring	π -Alkyl	4.37
	A:Lys311	Ester carbonyl oxygen	Conventional hydrogen bond	1.55
	A:Leu353	Betuline C29*	Carbon hydrogen bond	2.01
	A:Leu353	Betuline C29'	Carbon hydrogen bond	1.87
	B:Asn350	Betuline C28'	Carbon hydrogen bond	2.16
	A:Gln393	Sulfonamide methyl group	Carbon hydrogen bond	2.32
	A:Leu394	Pyridine ring	π -Sigma	2.26
	B:Met30	Triazole ring	π -Sulfur	5.70
	B:Met30	Benzene ring	π -Sulfur	4.13
	B:Met30	Pyridine ring	π -Sulfur	5.67
	B:Phe26	Sulfonamide sulfur	π -Sulfur	5.76
	B:Leu353	Betuline C15'	Alkyl	5.29
	B:Leu394	Betuline C1'	Alkyl	5.45
	A:Leu353	Betuline C21'	Alkyl	4.30
	A:Leu27	Betuline C23'	Alkyl	4.84
	B:Leu394	Betuline C23'	Alkyl	3.82
	B:Leu394	Betuline C24'	Alkyl	3.02
	B:Leu353	Betuline C25'	Alkyl	4.79
	A:Met30	Betuline C27'	Alkyl	4.61
	A:Leu353	Betuline C30'	Alkyl	3.44
	A:Phe26	Betuline C1'	π -Alkyl	4.90
	A:Phe26	Betuline C11'	π -Alkyl	4.81
	B:Phe26	Betuline C12'	π -Alkyl	4.72
	B:Phe26	Betuline C25'	π -Alkyl	4.35
	B:Phe26	Betuline C26'	π -Alkyl	4.76
	A:Leu394	Benzene ring	π -Alkyl	4.88
	B:Leu27	Benzene ring	π -Alkyl	5.08
	A:Arg120	Sulfonamide oxygen	Conventional hydrogen bond	2.82
	A:Arg120	Sulfonamide oxygen	Conventional hydrogen bond	1.67
	A:Lys207	Triazole nitrogen	Conventional hydrogen bond	2.10
	A:His78	Sulfonamide nitrogen	Conventional hydrogen bond	2.73
	A:Asp177	Pyridine ring C2	Carbon hydrogen bond	2.65
	A:Asp178	Benzene ring	π -Anion	3.21
	A:Asp178	Pyridine ring	π -Anion	2.64
	A:His78	Sulfonamide sulfur	π -Sulfur	5.74
	A:His78	Triazole ring	π - π -Stacked	3.29
	A:His78	Pyridine ring	π - π -Stacked	4.47
	A:His78	Benzene ring	π - π -Stacked	4.43
	A:Tyr83	Chlorine atom	π -Alkyl	4.41
	A:Pro53	Pyridine ring	π -Alkyl	5.19
	A:Ala366	Pyridine ring	π -Alkyl	4.66

A:Pro53		Benzene ring	π -Alkyl	4.93
A:Arg73		Phosphonate oxygen	Conventional hydrogen bond	1.81
A:Arg73		Phosphonate oxygen	Conventional hydrogen bond	3.09
A:Ser205		Sulfonamide oxygen	Conventional hydrogen bond	3.03
A:Ser205		Sulfonamide oxygen	Conventional hydrogen bond	2.63
A:Lys207		Sulfonamide oxygen	Carbon hydrogen bond	2.15
A:Arg120		Triazole ring	π -Cation	4.00
A:His78		Pyridine ring	π - π -Stacked	3.62
A:His78		Benzene ring	π - π -Stacked	3.57
A:His78	9b	Triazole ring	π - π -Stacked	5.30
A:Ala293		Ethyl	Alkyl	4.06
A:Ala327		Ethyl	Alkyl	4.34
A:Met291		Ethyl	Alkyl	4.76
A:Met360		Ethyl	Alkyl	5.24
A:Phe244		Ethyl	π -Alkyl	5.26
A:Pro53		Pyridine ring	π -Alkyl	5.44
A:Ala366		Benzene ring	π -Alkyl	4.83
A:Arg73		Ester carbonyl oxygen	Conventional hydrogen bond	2.09
A:Arg73		Triazole nitrogen	Conventional hydrogen bond	1.65
A:Arg73		Ester carbonyl oxygen	Conventional hydrogen bond	2.86
A:Arg120		Ester oxygen	Conventional hydrogen bond	2.73
A:Lys207		Sulfonamide oxygen	Conventional hydrogen bond	2.38
A:His78		Sulfonamide nitrogen	Conventional hydrogen bond	2.86
A:Asn75		Ethyl group	Carbon hydrogen bond	2.15
A:Asp113	9c	Ethyl group	Carbon hydrogen bond	3.07
A:Asp113		Ethyl group	Carbon hydrogen bond	2.63
A:His78		Sulfonamide sulfur	π -Sulfur	4.43
A:His78		Pyridine ring	π - π -Stacked	3.97
A:His78		Benzene ring	π - π -Stacked	4.93
A:Pro53		Pyridine ring	π -Alkyl	5.19
A:Pro53		Benzene ring	π -Alkyl	4.62
A:Ala366		Pyridine ring	π -Alkyl	5.23
A:Arg73	9d	Triazole nitrogen	Conventional hydrogen bond	2.70
A:Arg73		Triazole nitrogen	Conventional hydrogen bond	2.05
A:Lys207		Sulfonamide oxygen	Conventional hydrogen bond	1.72
A:His78		Sulfonamide nitrogen	Conventional hydrogen bond	2.02
A:His78		Sulfonamide oxygen	Carbon hydrogen bond	2.95
A:His78		Methylene linker	Carbon hydrogen bond	2.92
A:His78		Benzene ring	π - π -Stacked	3.14
A:His78		Pyridine ring	π - π -Stacked	3.80
A:Phe244		Butyl group	π -Alkyl	5.39
A:Ala366		Pyridine ring	π -Alkyl	4.77
A:Lys367		Triazole nitrogen	Conventional hydrogen bond	2.22
B:Lys337		Sulfonamide oxygen	Carbon hydrogen bond	2.89
A:Thr129		Betuline C33'	Carbon hydrogen bond	2.20
A:Lys367		Triazole nitrogen	Carbon hydrogen bond	2.53
A:Asp177	9e	Betuline C29'	Carbon hydrogen bond	2.82
A:Glu332		Betuline C29'	Carbon hydrogen bond	3.07
A:Asp178		Betuline C28'	Carbon hydrogen bond	2.64
A:Glu332		Triazole carbon	Carbon hydrogen bond	2.71
B:Lys337		Benzene ring	π -Cation	3.55
B:Lys337		Pyridine ring	π -Cation	3.99

A:His78	Betuline C6'	π -Sigma	2.09
A:Pro53	Betuline C1'	Alkyl	4.93
A:Ala366	Betuline C27'	Alkyl	3.82
A:Lys367	Betuline C1'	Alkyl	4.80
A:Lys367	Betuline C10'	Alkyl	5.44
A:Lys367	Betuline C11'	Alkyl	4.80
A:Pro53	Betuline C23'	Alkyl	3.90
A:Ile335	Betuline C30'	Alkyl	4.04
A:His78	Betuline C5'	π -Alkyl	4.85
A:His78	Betuline C24'	π -Alkyl	3.86
A:His78	Betuline C25'	π -Alkyl	3.36
A:His78	Betuline C26'	π -Alkyl	3.33
A:Ile335	Triazole ring	π -Alkyl	4.94
B:Lys337	Benzene ring	π -Alkyl	5.08
B:Lys336	Pyridine ring	π -Alkyl	4.84

Compound Spectrum List Report

Analysis Info


Analysis Name D:\Data\Service_20220831\8QSAProp2.d
Method low_mass.m
Sample Name tune_poshigh_test1
Comment

Acquisition Date 9/13/2022 1:13:51 PM

Operator KM
Instrument impact II 1825265.10082

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4000 V	Set Dry Heater	200 °C
Scan Begin	100 m/z	Set End Plate Offset	-500 V	Set Dry Gas	3.0 l/min
Scan End	1000 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C



#	m/z	Res.	S/N	I	I %	FWHM
1	247.0553	15207	81856.7	20377568	100.0	0.0162
2	269.0362	36498	31220.0	8915149	43.7	0.0074

Figure S1. HR MS spectra of 8-*N*-(prop-2-ynyl)quinolinesulfonamide (**8a**)




Figure S2. ^1H NMR spectra of 8-*N*-(prop-2-ynyl)quinolinesulfonamide (**8a**)




Figure S3. ^{13}C NMR spectra of 8-*N*-(prop-2-ynyl)quinolinesulfonamide (**8a**)




Figure S4. HSQC spectra of 8-N-(prop-2-ynyl)quinolinesulfonamide (8a)




Figure S5. HMBC spectra of 8-N-(prop-2-ynyl)quinolinesulfonamide (8a)

Compound Spectrum List Report

Analysis Info


Analysis Name D:\Data\Service_20220831\8QSAProp.d
Method low_mass.m
Sample Name tune_poshigh_test1
Comment

Acquisition Date 9/13/2022 1:03:48 PM

Operator KM
Instrument impact II 1825265.10082

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4000 V	Set Dry Heater	200 °C
Scan Begin	100 m/z	Set End Plate Offset	-500 V	Set Dry Gas	3.0 l/min
Scan End	1000 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C



#	m/z	Res.	S/N	I	I %	FWHM
1	261.0699	32410	60509.1	1975905	100.0	0.0081

Figure S6. HR MS spectra of 8-*N*-methyl-*N*-(prop-2-ynyl)quinolinesulfonamide (**8b**)




Figure S7. ^1H NMR spectra of 8-*N*-methyl-*N*-(prop-2-ynyl)quinolinesulfonamide (**8b**)




Figure S8. ^{13}C NMR spectra of 8-*N*-methyl-*N*-(prop-2-ynyl)quinolinesulfonamide (**8b**)




Figure S9. HSQC spectra of 8-N-methyl-N-(prop-2-ynyl)quinolinesulfonamide (8b)




Figure S10. HMBC spectra of 8-*N*-methyl-*N*-(prop-2-ynyl)quinolinesulfonamide (**8b**)

Compound Spectrum List Report


Analysis Info

Analysis Name D:\Data\KM7QCI.d
 Method low_mass.m
 Sample Name TM Low concentration
 Comment

Operator KM
 Instrument impact II 1825265.10082

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4000 V	Set Dry Heater	240 °C
Scan Begin	100 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C



#	m/z	Res.	S/N	I	I %	FWHM
1	451.0741	46889	14570.0	5115211	100.0	0.0096
2	453.0711	42091	5173.1	1821962	35.6	0.0108
3	473.0557	37315	1641.0	630401	12.3	0.0127
4	475.0531	31446	613.5	237045	4.6	0.0151

Figure S11. HR MS spectra of 8-*N*-[1-(7-chloroquinolin-4-yl)-1*H*-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (**9a**)





Figure S12. ¹H NMR spectra of 8-*N*-[[1-(7-chloroquinolin-4-yl)-1*H*-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (**9a**)



```

Current Data Parameters
NAME      KM8P_Q_13C
EXPNO     1
PROCNO    1

F2 - Acquisition Parameters
Date_     20170302
Time      16.00
INSTRUM   FOURIER300
PROBHD    5 mm DUL BB-1H
PULPROG   zgpg30
TD         65536
SOLVENT   DMSO
NS         1024
DS         4
SWH        24414.063 Hz
FIDRES     0.372529 Hz
AQ         1.3421773 sec
RG         501.187
DW         20.480 usec
DE         6.50 usec
TE         293.5 K
D1         2.00000000 sec
D11        0.03000000 sec
D31        0.00000950 sec
D40        0.02898005 sec
L4         40
L5         57
P32        90.00 usec
TD0        1

===== CHANNEL f1 =====
SFO1       75.4878687 MHz
NUC1       13C
P1         9.50 usec
PLW1       50.00000000 W

===== CHANNEL f2 =====
SFO2       300.1812007 MHz
NUC2       1H
CPDPRG[2] waltz16
PCPD2      90.00 usec
PLW2       44.00000000 W
PLW12      0.39247000 W
PLW13      0.19741000 W

F2 - Processing parameters
SI         32768
SF         75.4803210 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40

```

Figure S13. ^{13}C NMR spectra of 8-N-[[1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (**9a**)




Figure S14. HSQC spectra of 8-*N*-[1-(7-chloroquinolin-4-yl)-1*H*-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (**9a**)




Figure S15. HMBC spectra of 8-*N*-[1-(7-chloroquinolin-4-yl)-1*H*-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (**9a**)

Compound Spectrum List Report

Analysis Info

Analysis Name	D:\Data\KMFosf.d	Operator	KM	
Method	low_mass.m	Instrument	impact II	1825265.10082
Sample Name	TM Low concentration			
Comment				

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4000 V	Set Dry Heater	240 °C
Scan Begin	100 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C




Figure S16. HR MS spectra of diethyl 2-[4-[methyl-(8-sulfamoylquinolyl)-1H-1,2,3-triazol-1-yl]]ethylphosphonate (**9b**)




Figure S17. ^1H NMR spectra of diethyl 2-[4-[methyl-(8-sulfamoylquinolyl)-1H-1,2,3-triazol-1-yl]]ethylphosphonate (**9b**)




Figure S18. ^{13}C NMR spectra of diethyl 2-{4-[methyl-(8-sulfamoylquinolyl)-1H-1,2,3-triazol-1-yl]}ethylphosphonate (**9b**)




Figure S19. HSQC spectra diethyl 2-{4-[methyl-(8-sulfamoylquinolyl)-1H-1,2,3-triazol-1-yl]}ethylphosphonate (**9b**)




Figure S20. HMBC spectra diethyl 2-[4-[methyl-(8-sulfamoylquinolyl)-1H-1,2,3-triazol-1-yl]]ethylphosphonate (**9b**)

Compound Spectrum List Report


Analysis Info

Analysis Name D:\Data\KMEster.d
Method low_mass.m
Sample Name TM Low concentration
Comment

Operator KM
Instrument impact II 1825265.10082

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4000 V	Set Dry Heater	240 °C
Scan Begin	100 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C



#	m/z	Res.	S/N	I	I %	FWHM
1	390.1239	22292	75359.1	20377458	100.0	0.0175

Figure S21 . HR MS spectra of ethyl 3-[[4-(8-sulfamoylquinolyl)methyl]-1*H*-1,2,3-triazol-1-yl]propanoate (**9c**)




Figure S22. ^1H NMR spectra of ethyl 3-[[4-(8-sulfamoylquinolyl)methyl]-1H-1,2,3-triazol-1-yl]propanoate (9c)




Figure S23 . ^{13}C NMR spectra of ethyl 3-[[4-(8-sulfamoylquinolyl)methyl]-1H-1,2,3-triazol-1-yl]propanoate (**9c**)




Figure S24. ¹HSCC spectra of ethyl 3-[[4-(8-sulfamoylquinolyl)methyl]-1H-1,2,3-triazol-1-yl]propanoate (9c)




Figure S25. ¹HMBC spectra of ethyl 3-[[4-(8-sulfamoylquinolyl)methyl]-1H-1,2,3-triazol-1-yl]propanoate (9c)

Compound Spectrum List Report


Analysis Info

Analysis Name D:\Data\KMBuyl.d
Method low_mass.m
Sample Name TM Low concentration
Comment

Operator KM
Instrument impact II 1825265.10082

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Active	Set Capillary	4000 V	Set Dry Heater	240 °C
Scan Begin	100 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set Charging Voltage	2000 V	Set Divert Valve	Source
		Set Corona	0 nA	Set APCI Heater	0 °C



#	m/z	Res.	S/N	I	I %	FWHM
1	346.1336	20957	86756.1	20377468	100.0	0.0165
2	368.1154	43608	36143.5	9331787	45.8	0.0084

Figure S26 . HR MS spectra of 8-N-[[1-(1-butyl)-1H-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (**9d**)




Figure S27 . ¹H NMR spectra of 8-N-[[1-(1-butyl)-1H-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (**9d**)




Figure S28. ^{13}C NMR spectra of 8-*N*-[[1-(1-butyl)-1*H*-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (9d)




Figure S29. HSQC spectra of 8-N-[[1-(1-butyl)-1H-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (9d)




Figure S30. HMBC spectra of 8-N-[[1-(1-butyl)-1H-1,2,3-triazol-4-yl]methyl]quinolinesulfonamide (9d)

Compound Spectrum List Report

Analysis Info

Analysis Name D:\Data\KMMeBetulinaPositive.d

Method low_mass.m

Sample Name TM Low concentration

Comment

Operator KM

Instrument impact II

1825265.10082

Acquisition Parameter

Source Type ESI

Ion Polarity

Positive

Set Nebulizer

0.3 Bar

Focus Active

Set Capillary

4000 V

Set Dry Heater

240 °C

Scan Begin 100 m/z

Set End Plate Offset

-500 V

Set Dry Gas

4.0 l/min

Scan End 1000 m/z

Set Charging Voltage

2000 V

Set Divert Valve


Source

Set Corona

0 nA

Set APCI Heater

0 °C



#	m/z	Res.	S/N	I	I %	FWHM
1	828.4732	36740	57187.3	20214546	100.0	0.0225
2	850.4540	54137	9022.8	3173013	15.7	0.0157
3	866.4274	43927	2836.8	980902	4.9	0.0197

Figure S31. HR MS spectra of 8-*N*-methyl-*N*-({1-[3 β , 28-diacetoxylup-20(29)-en-30-yl]-1*H*-1,2,3-triazol-4-yl)methyl}-quinolinesulfonamide (**9e**)




Figure S32. ^1H NMR spectra of 8-*N*-methyl-*N*-((1-[3 β , 28-diacetoxylup-20(29)-en-30-yl]-1*H*-1,2,3-triazol-4-yl)methyl)-quinolinesulfonamide (**9e**)




Figure S33 . ¹³C NMR spectra of 8-*N*-methyl-*N*-((1-[3β, 28-diacetoxylup-20(29)-en-30-yl]-1*H*-1,2,3-triazol-4-yl)methyl)-quinolinesulfonamide (9e)




Figure S34 . HSQC spectra of 8-*N*-methyl-*N*-((1-[3 β , 28-diacetoxylup-20(29)-en-30-yl]-1*H*-1,2,3-triazol-4-yl)methyl)-quinolinesulfonamide (**9e**)






Figure S35 . HMBC spectra of 8-*N*-methyl-*N*-([1-[β , 28-diacetoxylup-20(29)-en-30-yl]-1*H*-1,2,3-triazol-4-yl)methyl]-quinolinesulfonamide (**9e**)



Default DAD/Integration


Chromeleon (c) Dionex
Version 7.2.2.6686

Figure S36. HPLC analysis of 8-*N*-{[1-(7-chloroquinolin-4-yl)-1*H*-1,2,3-triazol-4-yl]methyl}quinolinesulfonamide (**9a**)




Default DAD/Integration

Chromleon (c) Dionex
Version 7.2.2.6686**Figure S37.** diethyl 2-{4-[methyl-(8-sulfamoylquinolyl)-1H-1,2,3-triazol-1-yl]}ethylphosphonate (**9b**)




Default DAD/Integration

Chromeleon (c) Dionex
Version 7.2.2.6686**Figure S38.** ethyl 3-[[4-(8-sulfamoylquinolyl)methyl]-1*H*-1,2,3-triazol-1-yl]propanoate (**9c**)



Default DAD/Integration

Chromeleon (c) Dionex
Version 7.2.2.6686**Figure S39.** 8-*N*-{[1-(1-butyl)-1*H*-1,2,3-triazol-4-yl]methyl}quinolinesulfonamide (9d)



Default DAD/Integration

Chromeleon (c) Dionex
Version 7.2.2.6586

Figure S40. 8-N-methyl-N-((1-[3 β , 28-diacetoxylup-20(29)-en-30-yl]-1H-1,2,3-triazol-4-yl)methyl)-quinolinesulfonamide (**9e**)